The Patented Medicine Prices Review Board (PMPRB) is pleased to announce the reappointment of Dr. Mitchell Levine of Hamilton, Ontario as Vice-chairperson of the Board for a second five-year term. Dr. Levine was reappointed by His Excellency the Governor General in Council, on the recommendation of Health Minister Jane Philpott (Markham-Stouffville, Ont.) following an open, … Read more
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued an Order on October 28, 2016 requiring that Baxalta Canada Corporation (Baxalta) provide the PMPRB with the pricing and sales information required by section 80 of the Patent Actand sections 3 and 4 of the Patented Medicines Regulations. The Order relates to the medicine Oncaspar, which is … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the first edition of the Market Intelligence Report, a new analytical research series that provides drug pricing and utilization information on specific therapeutic market segments that are important to Canadians. The report’s findings show the sales and use of these biologic drugs are … Read more
The Patented Medicine Prices Review Board will hold a public hearing into the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the firm that holds the patent for Soliris and sells the medicine in Canada. Further details on the public hearing and a case management conference will be announced at a later date. … Read more
Health Minister Leonna Aglukkaq (Nunavut) tabled the 2010 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate. The report provides detailed information on sales and price trends of patented drugs in Canada, including international price comparisons, patentees' compliance with the Board's price Guidelines, … Read more
